[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2016002856A - Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon. - Google Patents

Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon.

Info

Publication number
MX2016002856A
MX2016002856A MX2016002856A MX2016002856A MX2016002856A MX 2016002856 A MX2016002856 A MX 2016002856A MX 2016002856 A MX2016002856 A MX 2016002856A MX 2016002856 A MX2016002856 A MX 2016002856A MX 2016002856 A MX2016002856 A MX 2016002856A
Authority
MX
Mexico
Prior art keywords
preventing
treating diseases
diseases related
reduced density
interferon receptors
Prior art date
Application number
MX2016002856A
Other languages
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Andrei Yurievich Egorov
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr filed Critical Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmentpr
Publication of MX2016002856A publication Critical patent/MX2016002856A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a la medicina, en particular, a un método para prevenir y/o tratar una enfermedad asociada con una reducción en la densidad de los receptores del interferón, el método comprende la administración de una cantidad efectiva de glutaril histamina o una sal farmacéuticamente aceptable de la misma; dicha enfermedad puede ser hepatitis B, herpes, infección por el virus del papilloma, o esclerosis múltiple; la invención se refiere también a una composición farmacéutica para la prevención y/o tratamiento de las enfermedades asociadas con una reducción en la densidad de los receptores del interferón, en donde la composición comprende una cantidad efectiva de glutaril histamina o una sal farmacéuticamente aceptable de la misma; la invención resuelve un problema de proporciona un agente novedoso eficaz para superar una resistencia a la terapia con interferón en enfermedades seleccionadas del grupo que incluye la hepatitis B, el herpes, la infección por el virus del papiloma, o la esclerosis múltiple.
MX2016002856A 2013-09-03 2014-09-01 Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon. MX2016002856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2013140758/15A RU2595862C2 (ru) 2013-09-03 2013-09-03 Способ профилактики или лечения заболеваний, связанных с пониженной плотностью интерфероновых рецепторов
PCT/RU2014/000656 WO2015034400A1 (ru) 2013-09-03 2014-09-01 Способ профилактики или лечения заболеваний, связанных с пониженной плотностью интерфероновых рецепторов

Publications (1)

Publication Number Publication Date
MX2016002856A true MX2016002856A (es) 2016-06-22

Family

ID=52628732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002856A MX2016002856A (es) 2013-09-03 2014-09-01 Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon.

Country Status (14)

Country Link
US (1) US9730915B2 (es)
EP (1) EP3042664A4 (es)
JP (1) JP6415570B2 (es)
KR (1) KR20160048963A (es)
CN (1) CN105555292B (es)
CA (1) CA2943318A1 (es)
EA (1) EA035359B1 (es)
HK (1) HK1223299A1 (es)
IL (1) IL244207B (es)
MX (1) MX2016002856A (es)
RU (1) RU2595862C2 (es)
SG (1) SG11201601241YA (es)
UA (1) UA121022C2 (es)
WO (1) WO2015034400A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009673A1 (en) * 1987-06-02 1988-12-15 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
CN100536852C (zh) * 2002-07-15 2009-09-09 基利得科学公司 L-fmau在制备联合治疗乙型肝炎病毒感染的药物中的应用
US9504673B2 (en) * 2009-05-21 2016-11-29 LTD “Valenta-Intellekt” Agent for the prophylaxis and treatment of highly pathogenic infectious diseases
RU2438694C1 (ru) * 2010-12-23 2012-01-10 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения вирусных заболеваний

Also Published As

Publication number Publication date
EA035359B1 (ru) 2020-06-02
JP2016529323A (ja) 2016-09-23
IL244207A0 (en) 2016-04-21
CA2943318A1 (en) 2015-03-12
KR20160048963A (ko) 2016-05-04
US9730915B2 (en) 2017-08-15
EP3042664A4 (en) 2017-05-17
WO2015034400A1 (ru) 2015-03-12
RU2013140758A (ru) 2015-03-10
IL244207B (en) 2019-05-30
EP3042664A1 (en) 2016-07-13
US20160354345A1 (en) 2016-12-08
SG11201601241YA (en) 2016-03-30
HK1223299A1 (zh) 2017-07-28
CN105555292A (zh) 2016-05-04
EA201600227A1 (ru) 2016-06-30
CN105555292B (zh) 2020-01-10
JP6415570B2 (ja) 2018-10-31
RU2595862C2 (ru) 2016-08-27
UA121022C2 (uk) 2020-03-25

Similar Documents

Publication Publication Date Title
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ732507A (en) Improved compositions for treating muscular dystrophy
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
EP2583677A3 (en) Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
HRP20171898T1 (hr) Kombinacija direktno djelujućih antivirusnih sredstava i ribavirina za liječenje hcv bolesnika
WO2014134583A3 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
WO2014182643A3 (en) Methods for treating hcv infection
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
WO2015084741A3 (en) Methods of treating hepatitis c virus infection in subjects with cirrhosis
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
MX2018000240A (es) Metodos para tratar el vhc.
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
NZ714347A (en) Method of treating intracellular infection
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
MX2016002856A (es) Metodo para la prevencion o tratamiento de enfermedades asociadas con una reduccion en la densidad de receptores de interferon.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
EA201491652A1 (ru) Средство для лечения вирусного гепатита с